News | June 08, 2022
Merck and Ridgeback announce new data for investigational molnupiravir
Based on a post hoc analysis, fewer required respiratory interventions
Based on a post hoc analysis, fewer required respiratory interventions
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
It will be marketed under the brand name Molunamax
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)